A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by National University Hospital, Singapore
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01100827
First received: April 7, 2010
Last updated: December 10, 2013
Last verified: December 2013
  Purpose

To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC.

To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.


Condition Intervention
NSCLC
Other: EGFR mutation status in patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by National University Hospital, Singapore:

Study Start Date: February 2013
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
EGFR mutation status in patients Other: EGFR mutation status in patients

  Eligibility

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Sampling Method:   Probability Sample
Study Population

In order to determine the EGFR mutation status, data analysis will be performed on demographic data and medical records (i.e. case notes and pathology reports) from patient with advanced stage adenocarcinoma NSCLC

Criteria

Inclusion Criteria:

Nil

Exclusion Criteria:

Nil

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01100827

Contacts
Contact: Ross Andrew Soo, MBBS 65 6772 4624 ross_soo@nuhs.edu.sg

Locations
Singapore
National University Hospital Singapore Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS    65 6772 4624    ross_soo@nuhs.edu.sg   
Principal Investigator: Ross Soo, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT01100827     History of Changes
Other Study ID Numbers: NS01/03/10
Study First Received: April 7, 2010
Last Updated: December 10, 2013
Health Authority: Singapore: Domain Specific Review Boards

Keywords provided by National University Hospital, Singapore:
EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC
The association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014